337 related articles for article (PubMed ID: 17975478)
1. The molecules: mechanisms of arterial vasodilatation observed in the splanchnic and systemic circulation in portal hypertension.
Iwakiri Y
J Clin Gastroenterol; 2007; 41 Suppl 3():S288-94. PubMed ID: 17975478
[TBL] [Abstract][Full Text] [Related]
2. Splanchnic and systemic vasodilation: the experimental models.
Wiest R
J Clin Gastroenterol; 2007; 41 Suppl 3():S272-87. PubMed ID: 17975477
[TBL] [Abstract][Full Text] [Related]
3. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule.
Iwakiri Y; Groszmann RJ
Hepatology; 2006 Feb; 43(2 Suppl 1):S121-31. PubMed ID: 16447289
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial dysfunction in cirrhosis.
Iwakiri Y; Groszmann RJ
J Hepatol; 2007 May; 46(5):927-34. PubMed ID: 17391799
[TBL] [Abstract][Full Text] [Related]
5. Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state.
Abraldes JG; Iwakiri Y; Loureiro-Silva M; Haq O; Sessa WC; Groszmann RJ
Am J Physiol Gastrointest Liver Physiol; 2006 May; 290(5):G980-7. PubMed ID: 16603731
[TBL] [Abstract][Full Text] [Related]
6. Hemodynamic changes in splanchnic blood vessels in portal hypertension.
Colle I; Geerts AM; Van Steenkiste C; Van Vlierberghe H
Anat Rec (Hoboken); 2008 Jun; 291(6):699-713. PubMed ID: 18484617
[TBL] [Abstract][Full Text] [Related]
7. Splanchnic and systemic vasodilatation: the patient.
Tsai MH
J Clin Gastroenterol; 2007; 41 Suppl 3():S266-71. PubMed ID: 17975476
[TBL] [Abstract][Full Text] [Related]
8. Molecular Mechanisms Leading to Splanchnic Vasodilation in Liver Cirrhosis.
Di Pascoli M; Sacerdoti D; Pontisso P; Angeli P; Bolognesi M
J Vasc Res; 2017; 54(2):92-99. PubMed ID: 28402977
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of extrahepatic vasodilation in portal hypertension.
Hennenberg M; Trebicka J; Sauerbruch T; Heller J
Gut; 2008 Sep; 57(9):1300-14. PubMed ID: 18445644
[TBL] [Abstract][Full Text] [Related]
10. Hemodynamics in the isolated cirrhotic liver.
Zipprich A
J Clin Gastroenterol; 2007; 41 Suppl 3():S254-8. PubMed ID: 17975473
[TBL] [Abstract][Full Text] [Related]
11. Discrepant effects of inducible nitric oxide synthase modulation on systemic and splanchnic endothelial nitric oxide synthase activity and expression in cirrhotic rats.
Malyshev E; Tazi KA; Moreau R; Lebrec D
J Gastroenterol Hepatol; 2007 Dec; 22(12):2195-201. PubMed ID: 18031380
[TBL] [Abstract][Full Text] [Related]
12. Pathophysiology of portal hypertension.
Bosch J; Pizcueta P; Feu F; Fernández M; García-Pagán JC
Gastroenterol Clin North Am; 1992 Mar; 21(1):1-14. PubMed ID: 1568769
[TBL] [Abstract][Full Text] [Related]
13. Vasoactive factors and hemodynamic mechanisms in the pathophysiology of portal hypertension in cirrhosis.
Gatta A; Bolognesi M; Merkel C
Mol Aspects Med; 2008; 29(1-2):119-29. PubMed ID: 18036654
[TBL] [Abstract][Full Text] [Related]
14. Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis.
Bolognesi M; Di Pascoli M; Verardo A; Gatta A
World J Gastroenterol; 2014 Mar; 20(10):2555-63. PubMed ID: 24627591
[TBL] [Abstract][Full Text] [Related]
15. Circulating nitric oxide products do not solely reflect nitric oxide release in cirrhosis and portal hypertension.
Afzelius P; Bazeghi N; Bie P; Bendtsen F; Vestbo J; Møller S
Liver Int; 2011 Oct; 31(9):1381-7. PubMed ID: 21745317
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibition ameliorates the hyperdynamic state and decreases nitric oxide production in cirrhotic rats with portal hypertension and ascites.
López-Talavera JC; Levitzki A; Martínez M; Gazit A; Esteban R; Guardia J
J Clin Invest; 1997 Aug; 100(3):664-70. PubMed ID: 9239414
[TBL] [Abstract][Full Text] [Related]
17. Vascular deterioration in cirrhosis: the big picture.
Bosch J
J Clin Gastroenterol; 2007; 41 Suppl 3():S247-53. PubMed ID: 17975472
[TBL] [Abstract][Full Text] [Related]
18. Pathophysiology of portal hypertension.
Cichoz-Lach H; Celiński K; Słomka M; Kasztelan-Szczerbińska B
J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():231-8. PubMed ID: 18812641
[TBL] [Abstract][Full Text] [Related]
19. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
Laleman W; Van Landeghem L; Van der Elst I; Zeegers M; Fevery J; Nevens F
Gastroenterology; 2007 Feb; 132(2):709-19. PubMed ID: 17258737
[TBL] [Abstract][Full Text] [Related]
20. Role of nitric oxide synthase and cyclooxygenase in hyperdynamic splanchnic circulation of portal hypertension.
Xu J; Cao H; Liu H; Wu ZY
Hepatobiliary Pancreat Dis Int; 2008 Oct; 7(5):503-8. PubMed ID: 18842497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
